Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211335 | 0.91 | DRD2 (0.48) | DRD2HTR1AHTR2AEPHX1CNR1 | |
| SCHEMBL14693112 | 0.87 | DRD2 (0.49) | DRD2HTR1AHTR2AEPHX1ALDH1A1 | |
| SCHEMBL3210404 | 0.84 | DRD2 (0.51) | DRD2HTR1AHTR2AEPHX1CNR1 | |
| SCHEMBL12991483 | 0.80 | DRD2 (0.42) | DRD2HTR1AHTR2ACNR1CNR2 | |
| SCHEMBL12991187 | 0.77 | PDE10A (0.40) | DRD2HTR1AHTR2ATP53 | |
| SCHEMBL13343040 | 0.76 | SMAD3 (0.54) | DRD2HTR1AHTR2AALDH1A1KDM4E | |
| SCHEMBL1084995 | 0.73 | HIF1A (0.45) | DRD2HTR1AHTR2ACNR1CNR2 | |
| SCHEMBL3207639 | 0.73 | GAA (0.43) | ALDH1A1KDM4EMEN1GAAMAPK1 | |
| SCHEMBL937815 | 0.73 | KMT2A (0.43) | DRD2HTR1AHTR2ACNR1CNR2 | |
| SCHEMBL13157350 | 0.73 | DRD2 (0.41) | DRD2HTR1AHTR2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | KCNQ1, KCNQ2, KCNQ5 | DRD2 1304/4885HTR1A 678/4885HTR2A 538/4885 |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNQ5 | DRD2 1304/4885HTR1A 678/4885HTR2A 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.